| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.7660130 |
| P8608 | Fatcat ID | release_dhnno5rxzbbgjcnltvll6ixdbu |
| P953 | full work available at URL | https://www.science.org/doi/pdf/10.1126/science.7660130 |
| P3181 | OpenCitations bibliographic resource ID | 1425005 |
| P698 | PubMed publication ID | 7660130 |
| P50 | author | William G. Kaelin | Q1603351 |
| P2093 | author name string | J. A. DeCaprio | |
| O. Iliopoulos | |||
| A. Kibel | |||
| P2860 | cites work | Molecular and Cellular Biology | Q3319478 |
| Proceedings of the National Academy of Sciences of the United States of America | Q1146531 | ||
| American Journal of Human Genetics | Q4744249 | ||
| Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations | Q24317659 | ||
| Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein | Q24336629 | ||
| Elongin (SIII): A Multisubunit Regulator of Elongation by RNA Polymerase II | Q24336681 | ||
| Positive regulation of general transcription factor SIII by a tailed ubiquitin homolog | Q24564870 | ||
| SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene | Q28281071 | ||
| Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII | Q28565868 | ||
| Identification of the von Hippel-Lindau disease tumor suppressor gene | Q29618644 | ||
| Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties | Q29620009 | ||
| Identification of cellular proteins that can interact specifically with the T/ElA-binding region of the retinoblastoma gene product | Q29620442 | ||
| A human cDNA encoding the small subunit of RNA polymerase II transcription factor SIII. | Q34315990 | ||
| Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma | Q34320299 | ||
| Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype | Q34327355 | ||
| Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma | Q35807817 | ||
| Tumour suppression by the human von Hippel-Lindau gene product | Q41320477 | ||
| Mutations of the VHL tumour suppressor gene in renal carcinoma | Q42806703 | ||
| Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype | Q44847029 | ||
| Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus | Q67702316 | ||
| Internal protein sequence analysis: enzymatic digestion for less than 10 micrograms of protein bound to polyvinylidene difluoride or nitrocellulose membranes | Q68210701 | ||
| Rapid site-specific mutagenesis in plasmids | Q69819047 | ||
| P433 | issue | 5229 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ligases | Q410221 |
| tumor suppressor gene | Q422445 | ||
| tumor suppressor proteins | Q66764736 | ||
| P304 | page(s) | 1444-6 | |
| P577 | publication date | 1995-09-08 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C | |
| Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C | |||
| P478 | volume | 269 |
| Q92372140 | A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma |
| Q56783008 | A Genome-Wide Screen for Normally Methylated Human CpG Islands That Can Identify Novel Imprinted Genes |
| Q37939403 | A Zebrafish Model for VHL and Hypoxia Signaling |
| Q30830058 | A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes |
| Q38297454 | A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box. |
| Q36089988 | A novel VHLα isoform inhibits Warburg effect via modulation of PKM splicing |
| Q38084210 | A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer |
| Q37536867 | A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. |
| Q36222472 | A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. |
| Q44391338 | A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1). |
| Q34375157 | ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex |
| Q33725645 | Abnormalities in oxygen sensing define early and late onset preeclampsia as distinct pathologies |
| Q24655274 | Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex |
| Q44315086 | Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network. |
| Q37983134 | Adenovirus degradation of cellular proteins. |
| Q83620313 | Adrenomedullin promotes human endothelial cell proliferation via HIF-1α |
| Q34167307 | Agents That Stabilize Mutated von Hippel–Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHL Proteostasis |
| Q36458965 | Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design |
| Q42469993 | Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity |
| Q34127887 | Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. |
| Q24522556 | An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells |
| Q41882621 | An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma. |
| Q24538586 | Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery |
| Q42377198 | Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma |
| Q24529081 | Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and degradation of tumor necrosis factor receptor II |
| Q31087151 | Asb6, an adipocyte-specific ankyrin and SOCS box protein, interacts with APS to enable recruitment of elongins B and C to the insulin receptor signaling complex |
| Q37318235 | BC-box protein domain-related mechanism for VHL protein degradation |
| Q36544617 | BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. |
| Q41550178 | Basic mechanisms of transcript elongation and its regulation |
| Q59039146 | Beating a path to Myc |
| Q27933200 | Binding of elongin A or a von Hippel-Lindau peptide stabilizes the structure of yeast elongin C |
| Q43895788 | Binding to Elongin C inhibits degradation of interacting proteins in yeast |
| Q37574153 | Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53. |
| Q30472042 | Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers |
| Q35643695 | CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1/signal transducers and activators of transcription 3 signaling. |
| Q28594730 | CUL-4A is critical for early embryonic development |
| Q36421050 | Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor. |
| Q34593794 | Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins |
| Q63384166 | Characterization of Elongin C Functional Domains Required for Interaction with Elongin B and Activation of Elongin A |
| Q28252043 | Characterization of the Gene (VBP1) and Transcript for the von Hippel–Lindau Binding Protein and Isolation of the Highly Conserved Murine Homologue |
| Q44312255 | Clinicopathological Investigation of Vascular Endothelial Growth Factor and von Hippel–Lindau Gene-Related Protein Expression in Immunohistochemically Negative Pituitary Adenoma – Possible Involvement in Tumor Aggressiveness |
| Q41760778 | Combination of multiple alignment analysis and surface mapping paves a way for a detailed pathway reconstruction--the case of VHL (von Hippel-Lindau) protein and angiogenesis regulatory pathway |
| Q27336383 | Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome |
| Q46330651 | Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene |
| Q24682460 | Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function |
| Q26777412 | Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis |
| Q33925239 | Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha |
| Q34650624 | Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase |
| Q44467856 | Cullin-5 and cullin-2 play a role in the development of neuromuscular junction and the female germ line of Drosophila |
| Q36710400 | Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists |
| Q37634917 | Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. |
| Q36551258 | Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice |
| Q38001233 | Defining an Individualized Treatment Strategy for Metastatic Renal Cancer |
| Q29041391 | Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex |
| Q34474235 | Deregulation of genetic pathways in neuroendocrine tumors |
| Q73187074 | Detection of a novel germline mutation in the von Hippel-Lindau tumour-suppressor gene by fluorescence-labelled base excision sequence scanning (F-BESS) |
| Q33481999 | Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes |
| Q34216018 | Dihydroceramide-based response to hypoxia. |
| Q34217927 | Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. |
| Q34323668 | Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity |
| Q24644903 | Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes |
| Q35821979 | E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis |
| Q36121124 | E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation |
| Q28117345 | ELL2, a new member of an ELL family of RNA polymerase II elongation factors |
| Q73948185 | Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease |
| Q24336681 | Elongin (SIII): A Multisubunit Regulator of Elongation by RNA Polymerase II |
| Q46943877 | Elongin B/C recruitment regulates substrate binding by CIS. |
| Q37230912 | Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products |
| Q27934153 | Elongin from Saccharomyces cerevisiae. |
| Q73623166 | Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region |
| Q41102690 | Establishment and characterization of a renal cell carcinoma line from a patient with von Hippel-Lindau syndrome |
| Q36556357 | Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions |
| Q53668779 | Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas |
| Q77585469 | Expression of vascular endothelial growth factor in von Hippel-Lindau syndrome-associated papillary cystadenoma of the epididymis |
| Q73196702 | Expression of von Hippel-Lindau protein (VHL-P) in nontumorous and adenomatous human pituitaries |
| Q33733536 | Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium |
| Q35687676 | Familial Renal Cancer: Molecular Genetics and Surgical Management |
| Q34480137 | Familial neurogenic tumor syndromes |
| Q39798868 | Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. |
| Q50290819 | Formation of Elongin BC complex |
| Q50290824 | Formation of Elongin complex |
| Q33886538 | Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. |
| Q47775625 | Functions of the von Hippel–Lindau tumour suppressor protein |
| Q53847052 | Gene expression of GLUT isoforms and VHL in oral squamous cell carcinoma |
| Q33719533 | Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein |
| Q81267790 | Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy |
| Q36354841 | Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics |
| Q39023793 | Genetic predisposition to kidney cancer |
| Q52622727 | Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-α binding site in VHL protein |
| Q41754374 | Genotype-phenotype analysis of von Hippel-Lindau syndrome in fifteen Indian families. |
| Q34135425 | Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype |
| Q55312690 | Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: an extended study of 77 families. |
| Q58862079 | Germline mutations detected in the von Hippel-Lindau disease tumor suppressor gene by Southern blot and direct genomic DNA sequencing |
| Q39899501 | Granulocytic differentiation of HL-60 promyelocytic leukemia cells is associated with increased expression of Cul5. |
| Q24599672 | HECT and RING finger families of E3 ubiquitin ligases at a glance |
| Q47385275 | HIF activation by pH-dependent nucleolar sequestration of VHL. |
| Q36609852 | HIF and fumarate hydratase in renal cancer |
| Q35086143 | HIF hydroxylation and the mammalian oxygen-sensing pathway |
| Q35550217 | HIF-1 as a target for drug development |
| Q35891283 | HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation |
| Q35777630 | HIF1 and oxygen sensing in the brain |
| Q35176799 | HIF1α and HIF2α exert distinct nutrient preferences in renal cells |
| Q37299459 | HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. |
| Q42858934 | Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes |
| Q37412363 | Hereditary kidney cancer syndromes |
| Q41046229 | High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation |
| Q35855588 | Human placental hypoxia-inducible factor-1alpha expression correlates with clinical outcomes in chronic hypoxia in vivo. |
| Q47893488 | Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? |
| Q34536583 | Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells |
| Q29615931 | Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein |
| Q37234734 | Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer |
| Q56777108 | Hypoxia-inducible Expression of a Naturalcis-Antisense Transcript Inhibits Endothelial Nitric-oxide Synthase |
| Q40127751 | Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. |
| Q36342313 | Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2 |
| Q28216741 | Identification and biochemical characterization of a novel transcription elongation factor, Elongin A3 |
| Q22253246 | Identification and characterization of Elongin A2, a new member of the Elongin family of transcription elongation factors, specifically expressed in the testis |
| Q48043968 | Identification of Elongin C Sequences Required for Interaction with the von Hippel-Lindau Tumor Suppressor Protein |
| Q24634004 | Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma |
| Q98623305 | Identification of anti-tumoral feedback loop between VHLα and hnRNPA2B1 in renal cancer |
| Q24654714 | Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex |
| Q33359573 | Identifying determinants of cullin binding specificity among the three functionally different Drosophila melanogaster Roc proteins via domain swapping |
| Q73227598 | Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues |
| Q35189579 | Impact of Genetics on the Diagnosis and Treatment of Renal Cancer |
| Q28590550 | Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice |
| Q39500622 | Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells |
| Q77113259 | Inherited Carcinomas of the Kidney |
| Q33961993 | Inherited renal cancer |
| Q44043145 | Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein |
| Q24336629 | Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein |
| Q41242833 | Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression. |
| Q38563753 | Lessons from the p53 mutant mouse |
| Q44121094 | Leu-574 of HIF-1alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway |
| Q35139337 | Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response |
| Q52549497 | Mammalian elongin A is not essential for cell viability but is required for proper cell cycle progression with limited alteration of gene expression. |
| Q63384164 | Mechanism and regulation of transcriptional elongation and termination by RNA polymerase II |
| Q63384163 | Mechanism of Action of RNA Polymerase II Elongation Factor Elongin |
| Q40401298 | Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases |
| Q41099828 | Mechanisms of carcinogenesis and the mutant mouse |
| Q26999077 | Mechanisms of chemical carcinogenesis in the kidneys |
| Q24600512 | Metabolism of Kidney Cancer: From the Lab to Clinical Practice |
| Q34417804 | Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab |
| Q42750834 | Molecular Analysis of the von Hippel-Lindau Disease Gene |
| Q74736163 | Molecular Genetics of Renal Cell Carcinoma |
| Q28220414 | Molecular basis of the VHL hereditary cancer syndrome |
| Q54352254 | Molecular characterization of large deletions in the von Hippel-Lindau (VHL) gene by quantitative real-time PCR: the hypothesis of an alu-mediated mechanism underlying VHL gene rearrangements |
| Q34065685 | Molecular diagnosis and therapy of kidney cancer |
| Q33544625 | Molecular diagnosis of inherited diseases |
| Q46987500 | Molecular identification and expression of differentially regulated genes of the European flounder, Platichthys flesus, submitted to pesticide exposure |
| Q36540580 | Molecular targeting therapy for renal cell carcinoma |
| Q36334896 | Molecularly targeted therapy in renal cell carcinoma |
| Q74825193 | Murine tumor suppressor models |
| Q77985962 | Mutations in the von Hippel-Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma |
| Q29937783 | Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC |
| Q41605739 | Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. |
| Q37286026 | Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein |
| Q34246723 | Negative regulators of cytokine signaling |
| Q34558244 | Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer |
| Q73666190 | Novel roles for elongin C in yeast |
| Q24314641 | Nuclear receptor binding protein 1 regulates intestinal progenitor cell homeostasis and tumour formation |
| Q37701211 | Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density |
| Q41352439 | Oncoprotein networks |
| Q42831594 | Overexpression of the MEN/ELL Protein, an RNA Polymerase II Elongation Factor, Results in Transformation of Rat1 Cells with Dependence on the Lysine-rich Region |
| Q91940247 | Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicine |
| Q35565483 | Oxygen sensing in cancer |
| Q26827518 | Oxygen sensing in retinal health and disease |
| Q28647626 | Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein |
| Q28509160 | Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis |
| Q37002164 | Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α. |
| Q42662265 | Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations |
| Q30471573 | Pheochromocytoma in von Hippel-Lindau Disease: Clinical Presentation and Mutation Analysis in a Large, Multigenerational Kindred1 |
| Q38786652 | Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function |
| Q28198423 | Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53 |
| Q37285776 | Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene |
| Q36161153 | Proline hydroxylation and gene expression |
| Q33868951 | Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells |
| Q34017147 | Protein degradation machinery is present broadly during early development in the sea urchin |
| Q41732732 | Proteolysis and the G1-S transition: the SCF connection |
| Q33728900 | RASSF6 promotes p21(Cip1/Waf1)-dependent cell cycle arrest and apoptosis through activation of the JNK/SAPK pathway in clear cell renal cell carcinoma |
| Q26853207 | RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis |
| Q33292271 | RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program |
| Q73561184 | Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2 |
| Q38071583 | Rational Therapy for Renal Cell Carcinoma Based on its Genetic Targets |
| Q34064359 | Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma |
| Q47071984 | Reduction of Cullin-2 in somatic cells disrupts differentiation of germline stem cells in the Drosophila ovary |
| Q24523680 | Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 |
| Q24537294 | Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. |
| Q24291025 | Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway |
| Q36659549 | Regulation of angiogenesis by hypoxia and hypoxia-inducible factors |
| Q42828009 | Regulation of c- fos expression by RNA polymerase elongation competence 1 1Edited by K. Yamamoto |
| Q30864043 | Regulation of gene expression for neurotransmitters during adaptation to hypoxia in oxygen-sensitive neuroendocrine cells |
| Q24301119 | Regulation of receptor for activated C kinase 1 protein by the von Hippel–Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness |
| Q28586399 | Regulation of ubiquitin ligase dynamics by the nucleolus |
| Q73669457 | Renal cell carcinoma |
| Q71974434 | Renal cysts, renal cancer and von Hippel-Lindau disease |
| Q50999477 | Renal involvement in von Hippel-Lindau disease |
| Q36564321 | Repression of gene expression by an exogenous sequence element acting in concert with a heterogeneous nuclear ribonucleoprotein-like protein, Nrd1, and the putative helicase Sen1 |
| Q27930029 | Requirement of ELC1 for RNA polymerase II polyubiquitylation and degradation in response to DNA damage in Saccharomyces cerevisiae |
| Q42207575 | Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways |
| Q84980204 | Retina-specific activation of a sustained hypoxia-like response leads to severe retinal degeneration and loss of vision |
| Q35078332 | Retracted: Up-Regulation of pVHL along with Down-Regulation of HIF-1α by NDRG2 Expression Attenuates Proliferation and Invasion in Renal Cancer Cells |
| Q35990141 | Role of VHL gene mutation in human cancer |
| Q33918504 | Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis |
| Q45230739 | Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein |
| Q33307879 | Role of the ubiquitin proteasome system in renal cell carcinoma |
| Q33836070 | Screening children at risk of developing inherited endocrine neoplasia syndromes |
| Q39722266 | Software and database for the analysis of mutations in the VHL gene |
| Q35238725 | Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. |
| Q36945200 | Structural Insights into the Folding Defects of Oncogenic pVHL Lead to Correction of Its Function In Vitro |
| Q28247009 | Structure and function of RNA polymerase II elongation factor ELL. Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex |
| Q24657293 | Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein |
| Q37401350 | Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation |
| Q41011329 | Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent |
| Q24563543 | Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein |
| Q35667690 | TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype |
| Q24296285 | TIP120A associates with cullins and modulates ubiquitin ligase activity |
| Q36725619 | Targeted molecular therapy for renal cell carcinoma |
| Q40192315 | Targeted therapy for renal cell carcinoma: a new treatment paradigm |
| Q34043797 | Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation |
| Q56777120 | Targeting SUMO E1 to Ubiquitin Ligases |
| Q64253749 | Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" |
| Q37331862 | Targeting the Met signaling pathway in renal cancer. |
| Q48027284 | The Elongin BC complex and the von Hippel–Lindau tumor suppressor protein |
| Q35211894 | The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families |
| Q50026055 | The HIF and other quandaries in VHL disease |
| Q47920723 | The Molecular Genetics of Endocrine Tumours |
| Q36029941 | The RNA polymerase II general elongation factors |
| Q35971082 | The Role of Elongin BC-Containing Ubiquitin Ligases |
| Q28205975 | The SOCS box: a tale of destruction and degradation |
| Q37987879 | The SOCS box—Adapting proteins for ubiquitination and proteasomal degradation |
| Q37064867 | The VHL tumor suppressor and HIF: insights from genetic studies in mice |
| Q36134573 | The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. |
| Q24634592 | The VHL tumor suppressor: master regulator of HIF |
| Q77572384 | The VHL tumour-suppressor gene paradigm |
| Q35210967 | The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician |
| Q37201797 | The clinical implications of the genetics of renal cell carcinoma |
| Q24654107 | The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation |
| Q44043146 | The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma |
| Q37832970 | The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors |
| Q52569852 | The elongin B ubiquitin homology domain. Identification of Elongin B sequences important for interaction with Elongin C. |
| Q39021700 | The epigenetic landscape of renal cancer |
| Q34087148 | The genetic basis of kidney cancer: a metabolic disease |
| Q34376363 | The hypoxia-inducible factor and tumor progression along the angiogenic pathway. |
| Q28582367 | The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex |
| Q27023273 | The metabolic basis of kidney cancer |
| Q36437759 | The molecular basis of von Hippel-Lindau disease |
| Q41718644 | The molecular pathology of urological malignancies |
| Q34660062 | The multifaceted von Hippel-Lindau tumour suppressor protein |
| Q28291161 | The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3) |
| Q34235680 | The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy |
| Q34035063 | The role of the cullin-5 e3 ubiquitin ligase in the regulation of insulin receptor substrate-1. |
| Q26746044 | The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions |
| Q33384295 | The ubiquitin system, disease, and drug discovery |
| Q35564185 | The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing |
| Q40023447 | The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter Activity |
| Q34748818 | The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix |
| Q37272653 | The von Hippel-Lindau gene: turning discovery into therapy |
| Q34087732 | The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression |
| Q36253857 | The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing |
| Q28206541 | The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription |
| Q41376765 | The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis |
| Q34132816 | The von Hippel-Lindau tumor suppressor protein |
| Q35201819 | The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity |
| Q44764282 | The von Hippel-Lindau tumor suppressor protein is a molten globule under native conditions: implications for its physiological activities |
| Q34569380 | The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing |
| Q50693009 | The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2. |
| Q24304165 | The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1 |
| Q35036600 | The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. |
| Q24564802 | The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins |
| Q33656394 | The von Hippel-Lindau tumour suppressor protein: new perspectives |
| Q34744818 | The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal |
| Q38871343 | Therapeutic Strategies for Hereditary Kidney Cancer |
| Q36206632 | Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development |
| Q54509706 | Three novel mutations in the von Hippel-Lindau tumour suppressor gene in Italian patients |
| Q38114944 | Tivozanib for the treatment of metastatic renal cancer |
| Q38858270 | Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms |
| Q22254253 | Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila |
| Q37353465 | Transcription syndromes and the role of RNA polymerase II general transcription factors in human disease |
| Q24530637 | Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein |
| Q41110818 | Transcriptional elongation and cancer. Tumorigenesis |
| Q37846387 | Tumor Biology and Prognostic Factors in Renal Cell Carcinoma |
| Q34303968 | Tumor Suppression and Transcription Elongation: The Dire Consequences of Changing Partners |
| Q41625163 | Tumor Suppressor Genes and Human Cancer |
| Q33788736 | Tumor suppressor genes in ophthalmology |
| Q58323648 | Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth |
| Q73111250 | Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene |
| Q37645058 | USP9X destabilizes pVHL and promotes cell proliferation |
| Q36946774 | Ubiquitin ligases in cancer: ushers for degradation |
| Q29615928 | Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein |
| Q42851011 | Up-Regulation of Vascular Endothelial Growth Factor in Stromal Cells of Hemangioblastomas Is Correlated with Up-Regulation of the Transcription Factor HRF/HIF-2α |
| Q28140184 | Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function |
| Q37774569 | Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma |
| Q34178821 | VEGF in brain tumors |
| Q34406737 | VEGF-targeted therapy in metastatic renal cell carcinoma |
| Q37154944 | VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo |
| Q54943750 | VHL and Hypoxia Signaling: Beyond HIF in Cancer. |
| Q37038901 | VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment |
| Q33967117 | VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling |
| Q35641669 | VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail |
| Q21144205 | VHL type 2B mutations retain VBC complex form and function |
| Q34455226 | VHL, the story of a tumour suppressor gene |
| Q24322407 | VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases |
| Q37166626 | VHLdb: A database of von Hippel-Lindau protein interactors and mutations |
| Q41221212 | Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas |
| Q34091273 | Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. |
| Q51971299 | Von Hippel-Lindau disease |
| Q34305239 | Von Hippel-Lindau disease: clinical and molecular perspectives |
| Q34448830 | Von Hippel-Lindau disease: gene to bedside |
| Q41547229 | Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene |
| Q26740274 | WSB1: from homeostasis to hypoxia |
| Q42373787 | William Kaelin, Peter Ratcliffe, and Gregg Semenza receive the 2016 Albert Lasker Basic Medical Research Award. |
| Q80687806 | [Molecular biology of the clear cell renal cell carcinoma: principles for a selective treatment] |
| Q34753344 | pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation |
| Q24684757 | pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2 |
| Q28589604 | pVHL function is essential for endothelial extracellular matrix deposition. |
| Q37275211 | pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development |
| Q44480238 | pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion. |
| Q73979850 | von Hippel-Lindau Disease |
| Q58918696 | von Hippel-Lindau Protein Induces Hypoxia-regulated Arrest of Tyrosine Hydroxylase Transcript Elongation in Pheochromocytoma Cells |
| Q24554216 | von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination |
| Q44548991 | von Hippel-Lindau protein complex is regulated by cell density |
Search more.